Heartsciences INC 8-K filings

HeartSciences Inc. received a notice from Nasdaq for failing to meet minimum stockholders' equity requirements, with a proposed merger cited as a potential solution to regain compliance.

HeartSciences Inc. announced its preliminary proxy statement filing for a business combination with Fortitude Mining Holdings, Inc., alongside its fiscal 2026 financial results and business updates.

HeartSciences Inc. has filed an 8-K/A to supplement its prior 8-K filing regarding the merger agreement with Fortitude Mining Holdings, Inc., providing necessary financial statements and pro forma information.

HeartSciences Inc. has entered into Amendment No. 1 to its Agreement and Plan of Merger with Fortitude Mining Holdings, Inc., modifying key terms related to LLC agreements and shareholder action.

HeartSciences Inc. announced the filing of its fiscal 2026 Form 10-K and anticipates filing a preliminary proxy statement for its proposed merger with Fortitude Mining Holdings, Inc.

HeartSciences Inc. announced an amendment to its CFO's employment agreement and a grant of restricted stock units, both effective July 7, 2026, tied to a pending merger.

HeartSciences has entered into a definitive merger agreement with Fortitude Mining Holdings and announced a comprehensive leadership transition.

HeartSciences Inc. reports results from its 2026 Annual Meeting, including director election and equity plan approval.

HeartSciences Inc. announced the passing of its Chief Operating Officer, Mark Hilz, on April 1, 2026, with no immediate plans to replace the role.

HeartSciences reported no meaningful revenue for its fiscal third quarter 2026 but highlighted significant progress in commercializing its MyoVista Insights platform and submitting its MyoVista wavECG device to the FDA.

HeartSciences Inc. has entered into an unsecured promissory note agreement with Streeterville Capital, LLC for $3 million in gross proceeds, carrying a 12% interest rate and an 18-month maturity.

HeartSciences Inc. board approved a new indemnification agreement for its directors and executive officers, enhancing protection against legal claims.

HeartSciences reported no meaningful revenue for fiscal Q2 2026, while making progress on its MyoVista Insights platform and submitting its wavECG device to the FDA.

HeartSciences Inc. announced an amendment to its 2023 Equity Incentive Plan, increasing the share pool to 1.25 million and granting restricted shares and RSUs to key executives and directors.

HeartSciences Inc. extended its loan maturity with Front Range Ventures to September 2026 and reported raising $6.7 million in gross proceeds from its Regulation A offering, alongside a $2.1 million debt-for-equity exchange.

HeartSciences Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement, closing a previously disclosed listing issue.

HeartSciences Inc. announced its first quarter fiscal 2026 financial results and provided a business update, highlighting the launch of MyoVista Insights and an FDA Breakthrough Device Designation.

HeartSciences Inc. announced it has raised $5.4 million through its Regulation A offering and exchanged $1.8 million in debt for common stock as of September 5, 2025.

HeartSciences Inc. announced it has raised $5.2 million through its Regulation A offering and reduced $1.655 million in debt by issuing common stock.

HeartSciences Inc. amended its at-the-market equity distribution agreement, increasing the potential capital raise to $25 million and adjusting sales agent commissions.

HeartSciences Inc. announced it has successfully raised $4.3 million through its Regulation A offering and reduced its debt by $1.1 million via a debt-to-equity exchange.

HeartSciences reported strategic progress in its AI-powered ECG technology, including the launch of its MyoVista Insights software platform and nearing FDA submission for its MyoVista wavECG device, while targeting commercialization and revenue in calendar 2026.

HeartSciences Inc. announced it has raised $2.8 million in gross proceeds from its Regulation A offering as of July 16, 2025, significantly below its maximum target of $15 million.

HeartSciences Inc. announced an increase in its equity incentive plan shares to 1,000,000, granted significant restricted stock units and stock options to executive officers and directors, and reported progress on its $15 million Regulation A offering and a debt-to-equity exchange.

HeartSciences Inc. has amended its bylaws to introduce a jury trial waiver for internal entity claims and establish a 3% ownership threshold for shareholders to initiate derivative proceedings, effective June 27, 2025.

HeartSciences Inc. announced it has received U.S. Food and Drug Administration Breakthrough Device designation for its Aortic Stenosis ECG algorithm, aiming to enable earlier detection of a serious heart valve disease.

HeartSciences Inc. has formalized its $15 million unit offering, including Series D Preferred Stock and warrants, and designated the Series D Preferred Stock, as part of its capital raising efforts.

HeartSciences Inc. announced it has been granted a foundational US patent for estimating echocardiography parameters indicative of heart function using an ECG, significantly expanding its intellectual property.

HeartSciences Inc. has officially designated 4,285,714 shares of Series D Convertible Preferred Stock, a key step in its previously announced offering to raise up to $15 million.

HeartSciences is working to regain compliance with Nasdaq listing rules while advancing its AI-ECG technology and pursuing FDA submissions.